Home  >  Research  >  Labs  >  Genome Biology and Genetics Program  >  MOLECULAR ENDOCRINOLOGY AND PHARMACOLOGY


Endocrinology and Pharmacology are the study of how hormones and pharmaceuticals act in the body respectively. At the molecular and cellular level, the focus is upon the receptors in the cell membranes that bind the hormones and pharmaceuticals, transmitting or blocking specific signals into our cells. The laboratory’s work is currently focused primarily on developing better treatments for kidney disease, cardiovascular disease and cancer.

This group mainly studies the molecular function of G protein-coupled receptors (GPCRs) and their signalling pathways, but is also starting to expand into other target classes such as receptor tyrosine kinases (RTKs), because of their importance in cancer in particular (Ayoub et al., 2013; O’Brien et al., 2018), and the Receptor for Advanced Glycation End-Products (RAGE), especially because of its importance in cardiovascular disease (Pickering et al., 2019).

GPCRs are a family of over 800 different cell surface sensors in the human body. Their function is diverse and, among many more, includes the detection of light (vision) and odorants (smell), as well as the regulation of growth, metabolism, reproduction, immune responses etc. Key GPCRs also have important roles in cancer, such as the chemokine receptors (Watts et al., 2013). Not surprisingly, between a third and a half of all currently available pharmaceuticals modulate GPCR function to mitigate various diseases and conditions.

The major research focus of the group is the study of receptor complexes and their role in receptor function. Receptors interact with a variety of different proteins as well as other receptors, and it is important to understand how the resultant complexes work in terms of signalling and regulation. The aim is to use this knowledge to develop substantially improved pharmaceuticals with fewer side effects.

Professor Kevin Pfleger

Professor Kevin Pfleger

Molecular Endocrinology and Pharmacology

Read more


$20M for biopharm DIMERIX to fund phase 3 trials for rare kidney disease

Biopharmaceutical company, Dimerix (ASX: DXB), which is developing new treatments for types of inflammatory kidney and respiratory diseases, announced it has successfully raised $20 million to fund Phase 3 trials with patients with the chronic kidney disease Focal Segmental Glomerulosclerosis (FSGS). FSGS is a rare kidney disease where inflammation and…

Read More

New tool to treat heart disease named WA innovator finalist

A new tool that provides cardiologists with rapid information to treat patients with heart disease and save lives lost from heart attacks is a finalist in the WA Innovator of the Year 2021 Awards. Apricot, an advanced coronary artery assessment tool, developed by a team of researchers from The University…

Read More

Bioengineers to the rescue, overcoming a common hospital problem

Whether you are in hospital for minor or major surgery it is almost certain you will need a catheter inserted, usually in your forearm, so fluids or medicine can be delivered. Worldwide, catheters are the most commonly used invasive medical device. In fact, up to 90% of hospital inpatients need…

Read More